Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.

Abstract	This 16-week study evaluated once-daily tazarotene 0.1% cream and adapalene 0.3% gel in patients with moderate-to-severe acne. Patients treated with tazarotene 0.1% cream performed better in many acne efficacy measures (reduction in lesion counts, percentage of patients achieving a 50 percent lesion count reduction, overall disease severity, investigator's global assessment) than did patients treated with adapalene 0.3% gel. Reduction in postinflammatory hyperpigmentation (PIH) was also significantly greater with tazarotene 0.1% cream than with adapalene 0.3% gel (P < or = 0.018). Irritation was infrequent, generally mild and similar between treatment groups. In conclusion, both tazarotene 0.1% cream and adapalene 0.3% gel were effective and well tolerated in patients with at least moderate acne. Tazarotene 0.1% cream appeared to be more effective and nearly as well tolerated as adapalene 0.3% gel in reducing acne lesions and was more effective than adapalene 0.3% gel in reducing PIH.
Authors	Emil Tanghetti, Sunil Dhawan, Lawrence Green, James Del Rosso, Zoe Draelos, James Leyden, Alan Shalita, Dee Anna Glaser, Pearl Grimes, Guy Webster, Pamela Barnett, Nicolas Le Gall
Journal	Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 9 Issue 5 Pg. 549-58 (May 2010) ISSN: 1545-9616 [Print] United States
PMID	20480800 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References	Dermatologic Agents Gels Naphthalenes Nicotinic Acids Adapalene tazarotene
Topics	Acne Vulgaris (drug therapy, pathology) Adapalene Administration, Cutaneous Adolescent Adult Child Dermatologic Agents (administration & dosage, adverse effects, therapeutic use) Female Gels Humans Hyperpigmentation (drug therapy, etiology) Male Middle Aged Naphthalenes (administration & dosage, adverse effects, therapeutic use) Nicotinic Acids (administration & dosage, adverse effects, therapeutic use) Severity of Illness Index Single-Blind Method Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!